NCT02601950 2025-06-22A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaIpsenPhase 2 Completed267 enrolled 25 charts 2 FDA
NCT01897571 2024-03-26Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLIpsenPhase 1/2 Completed400 enrolled 22 charts 2 FDA